Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;49(9):851-61.
doi: 10.1310/hpj4909-851.

Dalbavancin

Dennis J Cada  1 , Kyle Ingram  2 , Danial E Baker  3
Affiliations

Dalbavancin

Dennis J Cada et al. Hosp Pharm. 2014 Oct.

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The October 2014 monograph topics are ortitavancin diphosphate, insulin human inhalation powder, empaglifozin, efinaconazole topical solution, 10%, and tavaborole topical solution, 5%. The DUE/MUE is on oritavancin diphosphate.

PubMed Disclaimer

References

    1. Dalvance (dalbavancin) [prescribing information]. Chicago, IL: Durata Therapeutics; May2014.
    1. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407–1415. - PubMed
    1. Seltzer E, Dorr MB, Goldstein BP, et al; Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37(10):1298–1303. - PubMed
    1. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW.Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179. - PubMed
    1. Zyvox (linezolid) [prescribing information]. New York: Pharmacia & Upjohn Co; January2014.